Cross-company evaluation of the human lymphocyte activation assay. Issue 1 (1st January 2020)

• Record Type: Journal Article
• Authors: Collinge, Mark; Schneider, Patricia; Li, Dingzhou; Parish, Stanley; Dumont, Carolyne; Freebern, Wendy; Ghanime, Joseph; Guimont-Derochers, Fanny; Langenkamp, Anja; Lebron, Jose; Li, Nianyu; Marban, Celine; Plitnick, Lisa; Wheeler, Jennifer
• Is Part Of: Journal of immunotoxicology. Volume 17:Issue 1(2020)
• Page Start: 51
• Page End: 58
• Publication Date: 2020-01-01
• Subjects: Immune -- in vitro assay -- influenza -- immunosuppression -- PBMC -- cyclosporine -- mycophenolate; Immunotoxicology -- Periodicals; Poisons -- Immunology -- Periodicals; Environmental health -- Periodicals; 616.97
• DOI: 10.1080/1547691X.2020.1725694
• Languages: English
• ISSNs: 1547-691X

Abstract

Abstract: Nonclinical immunotoxicity evaluation is an important component of safety assessment for pharmaceuticals. One in vitro assay that can be applied in a weight of evidence assessment is the human lymphocyte activation (HuLA) assay, an antigen recall assay, similar in many respects to the in vivo T-cell-dependent antibody response (TDAR) in that cooperation of multiple immune cell types are needed to produce responses. This assay uses human cells and is more amenable than the TDAR to compound ranking and mechanistic studies. The HuLA assay requires less time and drug than TDAR assays, uses a relevant antigen (influenza), reflects a human immune response, and applies principles of the 3Rs to non-clinical safety assessment. Peripheral blood mononuclear cells (PBMC) from flu-immunized donors are re-stimulated with flu-vaccine in the presence of test articles, and proliferation is measured. Published data demonstrate the applicability of the HuLA assay, but it has not been evaluated for reproducibility across testing sites. To evaluate assay reproducibility, scientists from a consortium of institutions conducted the assay in parallel, using a common pool of donor PBMC, influenza vaccine, and known immunosuppressant compounds (cyclosporine A and mycophenolic acid). The HuLA assay was highly reproducible in identification of inhibition of antigen-specific responses, and there was significant agreement across testing sites in the half maximal inhibitory concentration (IC50 ) values. Intra-site variability was the largest contributor to the variability observed within the assay. The HuLA assay was demonstrated to be ideally suited to comparing multiple compounds (i.e. compound ranking or benchmarking) within the same assay. Overall, the data reported herein support the HuLA assay as a useful tool in mechanistic evaluations of antigen-specific immune responses.